Precision Biosciences (DTIL) Other Non-Current Assets (2018 - 2026)
Precision Biosciences (DTIL) reported Other Non-Current Assets of $203000.0 for Q1 2026, down 99.1% year-over-year from $22.6 million in Q1 2025, and down 1.46% on a QoQ basis from $206000.0 in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Other Non-Current Assets data on file, last reported at $203000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 99.1% year-over-year to $203000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $203000.0 (down 99.1% YoY) and the FY2025 annual result came in at $206000.0, down 99.09% from the prior year.
- Other Non-Current Assets retreated to $203000.0 in Q1 2026 per DTIL's latest filing, from $206000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $26.3 million in Q3 2025 and bottomed at $203000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $3.7 million (2022), against an average of $8.4 million.
- The widest annual swing landed in 2024, when Other Non-Current Assets surged 9930.67%; it then slumped 99.1% in 2026.
- Tracing DTIL's Other Non-Current Assets over 5 years: stood at $12.3 million in 2022, then slumped by 98.18% to $225000.0 in 2023, then surged by 9930.67% to $22.6 million in 2024, then tumbled by 99.09% to $206000.0 in 2025, then decreased by 1.46% to $203000.0 in 2026.
- Per Business Quant, the three latest DTIL Other Non-Current Assets figures stand at $203000.0 (Q1 2026), $206000.0 (Q4 2025), and $26.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | 203,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 203,000.00 |
| Dec 31, 2025 | 206,000.00 |
| Sep 30, 2025 | 26.30 Mn |
| Jun 30, 2025 | 208,000.00 |
| Mar 31, 2025 | 22.57 Mn |
| Dec 31, 2024 | 22.57 Mn |
| Sep 30, 2024 | 22.58 Mn |
| Mar 31, 2024 | 238,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Sep 30, 2023 | 234,000.00 |
| Jun 30, 2023 | 619,000.00 |
| Mar 31, 2023 | 2.75 Mn |
| Dec 31, 2022 | 12.35 Mn |
| Sep 30, 2022 | 9.52 Mn |
| Jun 30, 2022 | 9.33 Mn |
| Mar 31, 2022 | 4.66 Mn |
| Dec 31, 2021 | 4.64 Mn |
| Sep 30, 2021 | 4.22 Mn |
| Jun 30, 2021 | 1.87 Mn |
| Mar 31, 2021 | 1.81 Mn |
| Dec 31, 2020 | 1.72 Mn |
| Sep 30, 2020 | 1.56 Mn |
| Jun 30, 2020 | 1.36 Mn |
| Mar 31, 2020 | 572,000.00 |
| Dec 31, 2019 | 558,000.00 |
| Sep 30, 2019 | 392,000.00 |
| Jun 30, 2019 | 417,000.00 |
| Mar 31, 2019 | 453,000.00 |
| Dec 31, 2018 | 312,000.00 |